Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Acelyrin
Biotech
Acelyrin loses interest in izokibep, lays off 3rd of staff
Despite maintaining its recent winning streak in the clinic, Acelyrin is no longer focused on its former lead asset izokibep.
Darren Incorvaia
Aug 13, 2024 4:00pm
Sanofi, Pfizer, Acelyrin and more—Chutes & Ladders
May 10, 2024 8:30am
Acelyrin's proof-of-concept TED data cement Amgen challenge
Mar 20, 2024 7:00am
Acelyrin rebounds with psoriatic arthritis victory
Mar 11, 2024 10:59am
Could a CRO error explain Acelyrin's shocking phase 3 failure?
Nov 28, 2023 5:00am
Gene editor Metagenomi adds C-suite execs—Chutes & Ladders
Nov 10, 2023 9:30am